Adjuvant and neoadjuvant therapy with lapatinib in ErbB2-overexpressing breast cancer

被引：0
|
作者：
Janni, Wolfgang [1 ]
von Minckwitz, Gunter [2 ]
Moebus, Volker [3 ]
Nitz, Ulrike [4 ]
机构：
[1] Klinikum LMU Munchen, Klin & Poliklin Frauenheilkunde & Geburtshilfe, Munich, Germany
[2] GBG Forsch GmbH, Neu Isenburg, Germany
[3] Stadt Kliniken Frankfurt Hochst, Frankfurt, Germany
[4] Evangel Krankenhaus Bethesda, Brustzentrum Niederrhein, Monchengladbach, Germany
来源：
BREAST CARE | 2008年 / 3卷
关键词：
D O I：
10.1159/000119747
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 20
页数：4
相关论文
共 50 条
  • [1] Clinical experience with lapatinib in patients with ErbB2-overexpressing metastatic breast cancer
    Harbeck, Nadia
    Heinemann, Volker
    Loibl, Sibylle
    Untch, Michael
    [J]. BREAST CARE, 2008, 3 : 7 - 12
  • [2] Lapatinib Resistance Confers Cross-Resistance to Microtubule Inhibitors in ErbB2-Overexpressing Breast Cancer Cells
    Araki, K.
    Gallas, M.
    Liu, X.
    Jegg, A-M
    Ward, T.
    Pegram, M.
    [J]. CANCER RESEARCH, 2010, 70
  • [3] Future Roles of Lapatinib in ErbB2-Positive Breast Cancer: Adjuvant and Neoadjuvant Trials
    Costa, Serban-Dan
    Jackisch, Christian
    Thomssen, Christoph
    [J]. BREAST CARE, 2010, 5 : 22 - 24
  • [4] Molecular distinctions among ERBB2-overexpressing breast cancers
    SS Jeffrey
    [J]. Breast Cancer Research, 7
  • [5] Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway
    Lv, Sinan
    Zhang, Yunwu
    Song, Jiawei
    Chen, Jingruo
    Huang, Bohan
    Luo, Yuhan
    Zhao, Yuhua
    [J]. MEDICAL ONCOLOGY, 2022, 40 (01)
  • [6] Molecular distinctions among ERBB2-overexpressing breast cancers
    Jeffrey, SS
    [J]. BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S8 - S8
  • [7] Cerulenin suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway
    Sinan Lv
    Yunwu Zhang
    Jiawei Song
    Jingruo Chen
    Bohan Huang
    Yuhan Luo
    Yuhua Zhao
    [J]. Medical Oncology, 40
  • [8] A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)
    Janni, W.
    Sarosiek, T.
    Pikiel, J.
    Karaszewska, B.
    Staroslawska, E.
    Salat, C.
    Caglevic, C.
    Potemski, P.
    Brain, E.
    Briggs, K.
    de Silvio, M.
    Sapunar, F.
    Papadimitriou, C.
    [J]. CANCER RESEARCH, 2012, 72
  • [9] Differential effects of erbB3 and IGF-1R signaling on lapatinib resistance acquired by the erbB2-overexpressing breast cancer cells refractory to trastuzumab
    Lyu, Hui
    Huang, Jingcao
    Lee, Youngseok
    Liu, Bolin
    [J]. MOLECULAR CANCER RESEARCH, 2013, 11
  • [10] Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers
    Xia, Wenle
    Husain, Intisar
    Liu, Leihua
    Bacus, Sarah
    Saini, Shermini
    Spohn, Janice
    Pry, Karen
    Westlund, Ron
    Stein, Steven H.
    Spector, Neil L.
    [J]. CANCER RESEARCH, 2007, 67 (03) : 1170 - 1175
12345